Fluidx Reports Use of GPX Embolic Device in Challenging Tumor Case

January 20, 2022—Fluidx Medical Technology, a Salt Lake City, Utah–based company that is developing the GPX embolic device, announced that the GPX continues to be evaluated in a multicenter clinical trial.

The device is intended to stop blood flow for targeted treatment of hypervascular tumors, vessel malformations, internal bleeds, and other cancer-related uses. GPX is under development and does not have marketing clearance or approval in any market. It is available for investigational use only in New Zealand.

In the recent challenging case, Martin Krauss, MD, Head of Interventional Radiology at Christchurch Hospital in Christchurch, New Zealand, used the device to effectively devascularize a large tumor with multiple feeding vessels as part of a clinical trial.

“This could have been a challenging case since it involved a large renal tumor fed by small, low flow, tortuous vessels,” commented Dr. Krauss in the Fluidx press release. “We were able to use our standard embolic microcatheter to deliver GPX in a highly controlled fashion. Since we were not worried about catheter entrapment, we could take our time and ensure that we occluded all targeted vessels completely.”

Dr. Krauss further stated, “GPX flowed distally very well, completely filling the targeted region. Based on our case experiences, GPX is a great product for effectively filling distal vasculature.”

According to the company, the GPX technology is a low viscosity, aqueous-based solution in a syringe that solidifies into a durable embolus upon delivery without polymerization or dimethyl-sulfoxide precipitation. GPX is designed for simple preparation and quick material delivery to occlude blood vessels independent of a patient’s coagulation situation.

On November 2, 2021, Fluidx announced the presentation of data supporting the potential for oncology drug delivery with the GPX embolic device at the Symposium on Clinical Interventional Oncology conference held October 22-24 in Miami Beach, Florida.

In November 2020, the company reported on the investigational use of the GPX device by Andrew Holden, MBChB, to therapeutically devascularize a tumor via a transradial-access procedure. Dr. Holden presented the first patient-use cases with the GPX embolic device at LINC 2021, the Leipzig Interventional Course held January 25-29. Dr. Holden is Director of Interventional Radiology at Auckland City Hospital in Auckland, New Zealand.

Libble Ginster, CEO of Fluidx Medical Technology, stated in the press release, “Treating a tumor with multiple feeding vessels in a controlled, thorough manner without risk of catheter entrapment can improve patient care and minimize the need for follow-on procedures. GPX demonstrates improved control and precision. GPX does not require 20+ minutes of preparation time or the clinician to use a special catheter system. The simplicity of GPX preparation makes real-time clinical decision-making possible. We continue to be excited about the GPX portfolio and its future in advancing cancer care.”